These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33762075)

  • 21. Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis.
    Momin MAM; Thien SJ; Krittaphol W; Das SC
    J Pharm Biomed Anal; 2017 Feb; 135():133-139. PubMed ID: 28024261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.
    Feng Z; Miao Y; Peng Y; Sun F; Zhang Y; Li R; Ge S; Chen X; Song L; Li Y; Wang X; Zhang W
    BMC Infect Dis; 2023 May; 23(1):300. PubMed ID: 37158831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
    Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis.
    Dawson R; Diacon A
    Expert Opin Investig Drugs; 2013 Jul; 22(7):927-32. PubMed ID: 23687915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
    Kendall EA; Malhotra S; Cook-Scalise S; Denkinger CM; Dowdy DW
    BMC Infect Dis; 2019 Sep; 19(1):794. PubMed ID: 31500572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.
    Conde MB; Efron A; Loredo C; De Souza GR; Graça NP; Cezar MC; Ram M; Chaudhary MA; Bishai WR; Kritski AL; Chaisson RE
    Lancet; 2009 Apr; 373(9670):1183-9. PubMed ID: 19345831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
    Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
    BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis.
    Tasneen R; Li SY; Peloquin CA; Taylor D; Williams KN; Andries K; Mdluli KE; Nuermberger EL
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5485-92. PubMed ID: 21930883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Six-month therapy for abdominal tuberculosis.
    Jullien S; Jain S; Ryan H; Ahuja V
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012163. PubMed ID: 27801499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
    Mok J; Lee M; Kim DK; Kim JS; Jhun BW; Jo KW; Jeon D; Lee T; Lee JY; Park JS; Lee SH; Kang YA; Lee JK; Kwak N; Ahn JH; Shim TS; Kim SY; Kim S; Kim K; Seok KH; Yoon S; Kim YR; Kim J; Yim D; Hahn S; Cho SN; Yim JJ;
    Lancet; 2022 Oct; 400(10362):1522-1530. PubMed ID: 36522208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis.
    Ahmad Z; Tyagi S; Minkowski A; Peloquin CA; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2013 Jul; 188(1):97-102. PubMed ID: 23593945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study protocol.
    Padmapriyadarsini C; Devaleenal B; Ponnuraja C; Ramraj B; Singla R; Parmar M; Mattoo S; Mandal S
    BMJ Open; 2022 Aug; 12(8):e058606. PubMed ID: 36038181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretomanid: First Approval.
    Keam SJ
    Drugs; 2019 Nov; 79(16):1797-1803. PubMed ID: 31583606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers.
    Li M; Saviolakis GA; El-Amin W; Makhene MK; Osborn B; Nedelman J; Yang TJ; Everitt D
    Clin Pharmacol Drug Dev; 2021 Jun; 10(6):634-646. PubMed ID: 33378139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
    Tasneen R; Garcia A; Converse PJ; Zimmerman MD; Dartois V; Kurbatova E; Vernon AA; Carr W; Stout JE; Dooley KE; Nuermberger EL
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0239821. PubMed ID: 35315690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Half-century-old TB drugs get a facelift in new cocktails.
    Hutson S
    Nat Med; 2010 Dec; 16(12):1346. PubMed ID: 21135819
    [No Abstract]   [Full Text] [Related]  

  • 37. Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis.
    Ignatius EH; Abdelwahab MT; Hendricks B; Gupte N; Narunsky K; Wiesner L; Barnes G; Dawson R; Dooley KE; Denti P
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33229425
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis.
    Nuermberger E; Tyagi S; Tasneen R; Williams KN; Almeida D; Rosenthal I; Grosset JH
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1522-4. PubMed ID: 18285479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of 'Fixed Dose' versus 'Loose' Drug Regimens for Treatment of Pulmonary Tuberculosis in Two High TB-Burden African Countries: A Randomized Controlled Trial.
    Aseffa A; Chukwu JN; Vahedi M; Aguwa EN; Bedru A; Mebrahtu T; Ezechi OC; Yimer G; Yamuah LK; Medhin G; Connolly C; Rida W; Aderaye G; Zumla AI; Onyebujoh PC;
    PLoS One; 2016; 11(6):e0157434. PubMed ID: 27322164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis.
    Chen Z; Liang JQ; Wang JH; Feng SS; Zhang GY
    Tuberculosis (Edinb); 2015 Jul; 95(4):490-6. PubMed ID: 25964137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.